1. Kagu MB, Nggada HA, Garandawa HI, Askira BH, Durosinmi MA. AIDS-associated Kaposi's sarcoma in Northeastern Nigeria. Singapore Med J 2006;47:1069–1074.
2. Tamburro KM, Yang D, Poisson J, Fedoriw Y, Roy D, Lucas A,
et al. Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. Virology 2012;433:220–225.
3. Giffin L, Damania B. KSHV: pathways to tumorigenesis and persistent infection. Adv Virus Res 2014;88:111–159.
4. Goncalves PH, Uldrick TS, Yarchoan R. HIV-associated Kaposi sarcoma and related diseases. AIDS 2017;31:1903–1916.
5. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995;332:1181–1185.
6. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J,
et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996;2:925–928.
8. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186–1191.
9. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P,
et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276–1280.
10. Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V,
et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis 2010;51:350–358.
11. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335:123–128.
12. Roshan R, Labo N, Trivett M, Miley W, Marshall V, Coren L,
et al. T-cell responses to KSHV infection: a systematic approach. Oncotarget 2017;8:109402–109416.
13. Agaba PA, Sule HM, Ojoh RO, Hassan Z, Apena L, Mu'azu MA,
et al. Presentation and survival of patients with AIDS-related Kaposi's sarcoma in Jos, Nigeria. Int J STD AIDS 2009;20:410–413.
14. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993;54:26–36.
15. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in Indigenous Africans: burden, distribution, and trends. Lancet Oncol 2008;9:683–692.
17. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D,
et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 1996;93:14862–14867.
19. Gradoville L, Gerlach J, Grogan E, Shedd D, Nikiforow S, Metroka C,
et al. Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol 2000;74:6207–6212.
22. Majerciak V, Pripuzova N, McCoy JP, Gao SJ, Zheng ZM. Targeted disruption of Kaposi's sarcoma-associated herpesvirus ORF57 in the viral genome is detrimental for the expression of ORF59, K8alpha, and K8.1 and the production of infectious virus. J Virol 2007;81:1062–1071.
27. Alterman JF, Godinho B, Hassler MR, Ferguson CM, Echeverria D, Sapp E,
et al. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat Biotechnol 2019;37:884–894.
28. Mehta A, Michler T, Merkel OM. siRNA Therapeutics against respiratory viral infections-what have we learned for potential COVID-19 therapies? Adv Healthc Mater 2021;10:e2001650.
29. Sayers EW, Cavanaugh M, Clark K, Ostell J, Pruitt KD, Karsch-Mizrachi I. GenBank. Nucleic Acids Res 2020;48:D84–D86.
30. Zhang Z, Schwartz S, Wagner L, Miller W. A greedy algorithm for aligning DNA sequences. J Comput Biol 2000;7:203–214.
31. Okonechnikov K, Golosova O, Fursov M, team U. Unipro UGENE: a unified bioinformatics toolkit. Bioinformatics 2012;28:1166–1167.
34. Tafer H. Bioinformatics of siRNA design. (Gorodkin J, Ruzzo WL, eds.). In: RNA Sequence, Structure, and Function: Computational and Bioinformatic Methods Totowa: Humana Press, 2014. pp. 477–490.
35. Ichihara M, Murakumo Y, Masuda A, Matsuura T, Asai N, Jijiwa M,
et al. Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. Nucleic Acids Res 2007;35:e123.
38. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004;22:326–330.
39. Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun 2004;316:1050–1058.
40. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A,
et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004;32:936–948.
41. Matveeva O. What parameters to consider and which software tools to use for target selection and molecular design of small interfering RNAs. (Taxman DJ, ed.). In: siRNA Design: Methods and Protocols Totowa: Humana Press, 2013. pp. 1–16.
42. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 2000;16:276–277.
43. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403–410.
44. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2007;35:D61–D65.
45. Birmingham A, Anderson E, Sullivan K, Reynolds A, Boese Q, Leake D,
et al. A protocol for designing siRNAs with high functionality and specificity. Nat Protoc 2007;2:2068–2078.
46. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014;42:D68–D73.
53. Ashraf MI, Leema AA. Identification of micro-RNA seed sequences and other possible conserved motifs: an information theoretic approach. J RNAi Gene Silencing 2017;13:570–572.
54. Ishizuka A, Siomi MC, Siomi H. A
Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev 2002;16:2497–2508.
55. Fakhr E, Zare F, Teimoori-Toolabi L. Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther 2016;23:73–82.
59. Matveeva OV, Kang Y, Spiridonov AN, Saetrom P, Nemtsov VA, Ogurtsov AY,
et al. Optimization of duplex stability and terminal asymmetry for shRNA design. PLoS One 2010;5:e10180.
61. ElHefnawi M, Kim T, Kamar MA, Min S, Hassan NM, El-Ahwany E,
et al.
In silico design and experimental validation of siRNAs targeting conserved regions of multiple hepatitis C virus genotypes. PLoS One 2016;11:e0159211.
62. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S,
et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263–270.
63. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457–462.
64. Sugiyama T, Gursel M, Takeshita F, Coban C, Conover J, Kaisho T,
et al. CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. J Immunol 2005;174:2273–2279.
65. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K,
et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006;12:1188–1196.
69. Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F,
et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008;36:2136–2151.
70. Vidarsdottir L, Goroshchuk O, Kolosenko I, Palm-Apergi C. Designing siRNA and evaluating its effect on RNA targets using qPCR and western blot. (Gissberg O, Zain R, Lundin KE, eds.). In: Oligonucleotide-Based Therapies: Methods and Protocols New York: Springer, 2019. pp. 59–72.
72. Lu ZJ, Mathews DH. Efficient siRNA selection using hybridization thermodynamics. Nucleic Acids Res 2008;36:640–647.
73. Singh S, Gupta SK, Nischal A, Khattri S, Nath R, Pant KK,
et al. Design of potential siRNA molecules for hepatitis delta virus gene silencing. Bioinformation 2012;8:749–757.
74. Patzel V. In silico selection of active siRNA. Drug Discov Today 2007;12:139–148.
76. Yuan F, Gao ZQ, Majerciak V, Bai L, Hu ML, Lin XX,
et al. The crystal structure of KSHV ORF57 reveals dimeric active sites important for protein stability and function. PLoS Pathog 2018;14:e1007232.
77. Majerciak V, Yamanegi K, Nie SH, Zheng ZM. Structural and functional analyses of Kaposi sarcoma-associated herpesvirus ORF57 nuclear localization signals in living cells. J Biol Chem 2006;281:28365–28378.
78. Lee YS, Nakahara K, Pham JW, Kim K, He Z, Sontheimer EJ,
et al. Distinct roles for
Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 2004;117:69–81.
79. Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev 2005;19:517–529.
81. Fatahzadeh M. Kaposi sarcoma: review and medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:2–16.
82. Veraitch O, Bower M, Shackleton D, Stebbing J. Rituximab therapy for HIV-associated multicentric Castleman disease. HIV Ther 2010;4:281–284.
84. Steinberg I, Kimberlin DW. Acyclovir dosing and acute kidney injury: deviations and direction. J Pediatr 2015;166:1341–1344.
85. Wang K, Yang C, Ye J, Zeng F, Duan Y, Zheng Y,
et al. Inhibition activity of herpes virus (HSV) replication by α-TIF siRNA-loaded PLGA-TPGS nanoparticles
in vitro and
in vivo. J Biomed Nanotechnol 2017;13:717–726.
86. Gatault P, Jones IKA, Meyer C, Kreklywich C, Alexander T, Smith PP,
et al. Rat and human cytomegalovirus ORF116 encodes a virion envelope glycoprotein required for infectivity. Virology 2021;557:23–33.
87. Lu JF, Jin TC, Zhou T, Lu XJ, Chen JP, Chen J. Identification and characterization of a tumor necrosis factor receptor like protein encoded by Cyprinid Herpesvirus 2. Dev Comp Immunol 2021;116:103930.